



**MedXtractor Corp.**  
**Management Discussion and Analysis**  
*For the three and nine months ended November 30, 2020*

# MedXtractor Corp. Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

This management's discussion and analysis ("**MD&A**") of **MedXtractor Corp.** (the "**Company**", the "Corporation" or "MedX") contains an analysis of the Company's operational and financial results for the nine months ended November 30, 2020. This MD&A has been prepared by management as of December 29, 2020 and has been approved by the Company's Board of Directors. This MD&A should be read in conjunction with the Company's audited financial statements and related notes for the year ended February, 2020 and the unaudited interim consolidated condensed financial statements for the three and nine months ended November 30, 2020 and notes thereto, which have been prepared in accordance with International Financial Reporting Standards ("**IFRS**").

All dollar amounts referred to in this MD&A are expressed in Canadian dollars except where indicated otherwise. The Company's most recent filings are available under the Company's profile on the System for Electronic Document Analysis and Retrieval ("**SEDAR**") and can be accessed through the internet at [www.sedar.com](http://www.sedar.com).

## **Cautionary Note Regarding Forward-Looking Statements**

This MD&A contains "forward-looking information" within the meaning of Canadian securities legislation concerning the business, operations and financial performance and condition of the Company. Statements containing forward-looking information include, but are not limited to, statements with respect to anticipated developments in the Company's operations in future periods; planned activities; the adequacy of the Company's financial resources and other events or conditions that may occur in the future; the ability of the Company to create value for its shareholders; the ability of the Company to meet expected financing requirements. Generally, statements containing forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". Statements containing forward-looking information are based on the opinions and estimates of management as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such statements, including but not limited to risks related to: current global financial conditions; the need for additional financing and its availability on acceptable terms; the speculative nature of the cannabis industry; the ability to satisfy the financial needs required to maintain the Company's status as a going concern; the early stage of the Company's operations; the Company's need to rely on technical experts, which may not be available; future dilution to existing shareholders; certain uninsured or uninsurable risks; adverse effects on share prices from factors beyond the Company's control; as well as other factors discussed herein. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those expected in statements containing forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information that is included herein, except in accordance with applicable securities laws.

## **The Business**

MedX is a technology and marketing public company, incorporated on January 24, 2018 and has its head office in Calgary, Alberta, Canada. MedX is focused on the commercialization of its CO<sub>2</sub>-based and alcohol-

# MedXtractor Corp.

## Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

based essential oil extractors. MedX's technology allows for the extraction of essential oils and other compounds from a variety of botanical feedstock using carbon dioxide ("CO2") or alcohol as the extraction solvent. There are three capacities of CO2 extractors currently available; 2oz, 5oz and 16oz; and one alcohol-based extractor called the "Essential". All extractors are designed and built in Calgary, Canada and MedX holds both US and Canadian patents on its CO2-based technology. MedX began sales in June 2018 and has installations in multiple countries worldwide. MedX believes that CO2-based extraction provides the purest non-polar raw extracts available and that alcohol-based extractors are better for the extraction of polar compounds. Current demand is from the medical cannabis grower as consumption methods move away from smoking flower toward vaping, tinctures and edibles - all of which require extracts as a base. MedX technologies are 100% owned by MedX and there are no royalties or payments of any kind payable to any party anywhere in the world.

The Company's first public trading date was October 24, 2019, listed on the Canadian Securities Exchange (CSE:MXT).

### **Recent Corporate Developments, Business Initiative**

During the quarter, and subsequent there have been some very positive developments in the cannabis legalization and decriminalization movement. First, as recently reported by Forbes, "One thing is clear from the election results: American voters of all parties overwhelmingly support legalizing cannabis! Not only did cannabis initiatives run the table last night, winning legalization in Arizona, Montana, New Jersey, and South Dakota, and medical marijuana in Mississippi and South Dakota, they passed by massive and historic margins." President-elect Joe Biden has stated that cannabis reform is on the agenda and that decriminalization at a Federal level is a possibility.

On November 4, 2020 Gordon Crawford was appointed to the Board of Directors and Neil Runions resigned from the Board. Mr. Crawford owns 4.27% of issued and outstanding shares of MedX.

On September 10, 2020 the Company announced receipt of its Canadian patent for its CO2-based extraction process.

The Company recently added its new "Essential" alcohol-based essential oil extractor. The extractor was designed internally and MedX owns it 100%. Within the craft-scale horizontal our CO2-based extractors experience competition from alcohol-based (mainly ethanol) extractors. In our opinion, while CO2-based extracts constitute the highest purity and highest quality products, alcohol-based extracts can be used for other product sectors, primarily edibles, topicals and tinctures. Alcohol-based extractors are significantly less complex and less expensive to manufacture and can offer the craft grower a lower cost entry into the extract/concentrates market. Our strategy is to establish market share in the alcohol-based sector by offering a leading-edge product with higher functionality, and at a cheaper price than the competition. An additional competitive advantage is that we can offer a trade-in-based upgrade path from our new alcohol-based extractors to our premium Craft-scale CO2-based extractors, something our competitors cannot offer. We will also accept our competitor's products for trade-in. We believe that the introduction of this new product opens a new market segment to MedX; one that has the potential to not only increase sales overall, but to also drive our CO2 extractor sales to new heights worldwide.

On July 13, 2020 MedX incorporated its wholly-owned subsidiary, 2273670 Alberta Ltd., for the alcohol-based business. The results of the subsidiary incorporated during the year are included in the consolidated statements of income and comprehensive income from the date of incorporation.

In March 2020 there was a global outbreak of COVID-19 (coronavirus), which has had a significant impact on businesses through the restrictions put in place by the Canadian, provincial and municipal governments regarding travel, business operations and isolation/quarantine orders.

**MedXtractor Corp.**  
**Management Discussion and Analysis**

*For the three and nine months ended November 30, 2020*

We have experienced reduced customer inquiries and demand, supply chain disruptions, and increased government regulations, all of which have negatively impacted the Company's business and tempered our sales growth curve. We had temporary reductions in staff in response to these changes.

# MedXtractor Corp.

## Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

### Results of Operations

The following table outlines the details of operations for the three and nine months ended November 30, 2020 and 2019.

	3 Months Ended November 30, 2020	3 Months Ended November 30, 2019	9 Months Ended November 30, 2020	9 Months Ended November 30, 2019
<b>Revenues</b>				
Sales	\$ 185,829	\$ 191,806	\$ 448,592	\$ 392,111
Cost of Sales	86,857	71,489	196,250	158,370
<b>Gross margin</b>	<b>\$ 98,972</b>	<b>120,317</b>	<b>\$ 252,342</b>	<b>\$ 233,741</b>
<b>Expenses</b>				
Depreciation and amortization	\$ 192	79	\$ 707	\$ 79
Advertising and promotion	26,880	25,958	67,833	43,171
Warranty	21	-	211	-
Interest and bank charges	3,812	3,039	7,619	7,686
Contractors	15,500	7,393	32,500	20,387
Legal, audit, and professional	8,909	43,911	25,217	116,027
Travel, meals and entertainment	1,301	2,420	3,335	7,033
Research and development	1,710	1,327	9,830	7,543
Insurance	3,250	-	9,750	-
Investor relations	34,476	-	50,128	-
Office expenses	1,020	944	3,904	2,661
Accounting	1,800	1,787	4,800	5,882
Rent	2,100	2,100	4,900	6,300
Referral fees	-	-	153	1,450
Utilities	284	-	284	-
Stock based compensation	16,685	19,400	16,685	48,692
<b>Total expenses</b>	<b>\$ 117,940</b>	<b>\$ 108,358</b>	<b>\$ 237,856</b>	<b>\$ 266,911</b>
<b>Other Income</b>				
Foreign exchange gain (loss)	\$ (176)	\$ -	(2,648)	\$ -
Interest Income	330	1,499	1,214	2,391
<b>Total other income</b>	<b>\$ 154</b>	<b>\$ 1,499</b>	<b>\$ (1,434)</b>	<b>\$ 2,391</b>
<b>Net operating income (loss) and comprehensive income (loss)</b>	<b>\$ (18,814)</b>	<b>\$ 13,458</b>	<b>\$ 13,052</b>	<b>\$ (30,799)</b>

Revenue - For the nine months ended November 30, 2020 revenue was \$166,286 (November 30, 2019 - \$127,319) from Canadian customers and \$282,306 (November 30, 2019 - \$264,792) from international customers.

# MedXtractor Corp.

## Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

The fluctuation in sales, cost of sales and gross margin is primarily due to the startup nature of the Company. During the startup period many marketing approaches were tested and numerous mechanical design configuration changes were done to increase extractor performance. The configuration changes resulted in additional components with additional costs resulting in lower gross margins. Additionally, while the 16oz version provides the highest margin and sells the most units, it is also the version that has been most exposed to sales discounts, which may include free shipping and/or outright sales discounts. The addition of alcohol based products has reduced average per unit sales prices and margin.

Advertising and promotion, insurance, and investor relation costs have increased as the Company has grown while legal and professional expenses were significant while the Company was in process of its public listing in 2019.

Investor relation costs increased with market making activities and annual general meeting costs.

Research and development costs were incurred as the Company continued to refine its products and to start development of its new alcohol-based product line.

On October 4, 2020, the Company granted 200,000 common share purchase options to a consultant which are exercisable at a price of \$0.085 per share, expire in five years and vested immediately. The fair value of was calculated using the Black-Scholes option pricing model. The assumptions for this calculation were a risk free interest rate of 0.3%, expected life of 5 years and expected volatility of 166% resulting in stock based compensation expense of \$16,685.

### Summary of Quarterly Results

	Nov 30, 2020	Aug. 31, 2020	May 31, 2020	Feb. 29, 2020	Nov. 30, 2019	Aug. 31, 2019	May 31, 2019	Feb. 28, 2019
	\$	\$	\$	\$	\$	\$	\$	\$
Revenue	185,829	167,270	95,493	139,352	191,509	106,069	94,237	72,582
Cost of Sales	86,857	75,767	33,626	55,877	71,489	39,958	46,924	27,713
Gross Profit	98,972	91,503	61,867	83,475	120,020	66,111	47,313	44,869
Expenses (cash)	101,063	71,071	48,330	99,333	88,958	91,413	37,848	80,491
Expenses (non-cash)	16,877	262	253	6,551	19,400	-	29,292	459
Other income	154	(3,614)	2,026	16,887	1,499	667	225	277
Income (loss)	(18,814)	16,556	15,310	(5,522)	13,161	(24,635)	(19,602)	(35,804)
Net income (loss) per share	0.00	0.00	0.00	(0.00)	0.00	(0.00)	(0.00)	(0.00)
Total assets	698,889	706,918	688,128	673,843	640,513	630,057	271,315	269,172
Total long term liabilities	-	-	-	-	-	-	-	-
Cash dividend per share	-	-	-	-	-	-	-	-
Shares outstanding	25,746,425	25,746,425	25,746,425	25,746,425	21,062,600	20,892,491	20,700,100	20,700,100

The fluctuation in sales, cost of sales and gross margin is primarily due to the startup nature of the Company. During the startup period many marketing approaches were tested and numerous mechanical design configuration changes were done to increase extractor performance. Gross margins have varied, influenced as well by foreign currency changes, discounting and sales mix changes.

During the quarter ended November 30, 2019 MedX had its highest revenue levels of \$191,509. The significant increase in sales revenues are primarily due to seasonal harvest demand and the trend has subsequently normalized. This said, the combination of US Federal Hemp/CBD legalization, medical demand for extract purity due to the vape diluent issue and general demand for small-scale CO2-based extractors from the craft medical horizontal, is expected to support increasing organic growth going forward. With greater than 55% of sales now originating internationally, our growth prospects are worldwide and

# MedXtractor Corp. Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

independent of the Canadian market. Fall harvest typically would drive peak seasonal revenues in the quarter ended November 30, 2020. The global outbreak of COVID-19 (coronavirus) has caused a reduction in potential sales inquiries and sales.

## **Liquidity and Capital Resources**

At November 30, 2020, the company had working capital of \$658,509 including cash of \$596,094 as compared to working capital of \$629,909 including cash of \$594,492 as at February 29, 2020.

The Company's objective when managing capital is to maintain the confidence of shareholders and investors in the implementation of its business plans by maintaining sufficient levels of liquidity to fund and support its development as well as other corporate activities. Management monitors its financial position on an ongoing basis.

Financial statements have been prepared on a going concern basis which assumes that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

The Company is authorized to issue an unlimited number of common shares without par value.

## **Off Balance Sheet Arrangements**

The Company is not a party to any off-balance sheet arrangements or transactions.

## **Changes in Accounting Policies**

None. These consolidated financial statements include the financial statements of MedXtractor Corp. and its wholly-owned subsidiary, 2273670 Alberta Ltd., incorporated in Alberta on July 13, 2020. The results of the subsidiary incorporated during the year are included in the consolidated statements of income and comprehensive income from the date of incorporation. All intercompany transactions, balances, income and expenses are eliminated through the consolidation process. The accounts of the subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies.

## **Financial Instruments**

The Company, as part of its operations, carries financial instruments consisting of cash, accounts receivable, and accounts payable and accruals. It is management's opinion that the Company is not exposed to significant credit, interest, or currency risks arising from these financial instruments.

# MedXtractor Corp.

## Management Discussion and Analysis

For the three and nine months ended November 30, 2020

### Other MD&A Requirements

#### Outstanding Share Data

The Company's authorized share capital consists of an unlimited number of common shares without par value.

Equity instruments issued and outstanding:

	December 29, 2020	November 30, 2020	February 29 2020
Common shares	25,746,425	25,746,425	25,746,425
Warrants and Finders Warrants <sup>(1)</sup>	-	-	4,683,825
Stock Options	2,300,000	2,300,000	2,100,000
Fully Diluted	28,046,425	28,046,425	32,530,250

(1) Warrants and Finders Warrants were exercisable into one Common Share upon payment to the Company of \$0.20 on or before October 9, 2020, thus expired unexercised.

#### Related Party transactions

None

#### Proposed Transactions

None

#### Subsequent Events

None.

#### Risk Factors

##### Industry Risks

The Corporation faces competition in the market from larger more established companies in the cannabis technology industry that offer a wider array of products. These competitors may make it difficult for us to offer competing products and grow our business.

We will be competing with the producers of other products and competition in the cannabis technology industry that may limit the availability of channels required for the successful distribution of our products. Our products may be competing directly with other products and indirectly with other forms of CO2 extractors and other types of extractors. We may not be able to compete successfully against our future competitors and competition could have a material adverse effect on our business, results of operations and financial condition. Our potential competitors may develop superior products and services that achieve greater market acceptance than ours. Accordingly, failure of our marketing campaign may result in the failure of the business.



# MedXtractor Corp.

## Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

### **Industry changes may have a negative impact on our operations**

The extraction business, in general, is undergoing significant changes, primarily due to technological developments. These developments have resulted in the availability of alternative forms of extractors. It is impossible to accurately predict the effect that these and other new technological developments may have on the extraction industry. These uncertainties as well as others outlined herein may have a negative impact on our operations and could result in the complete failure of our business.

Our success depends on our ability to develop products and sell them directly through our website and indirectly through distribution channels. The inability to establish an effective website and distribution channels, may severely limit our growth prospects.

Our business success is completely dependent on our ability to develop products and secure direct and indirect distribution channels. Revenues derived therefrom represent vital funds for our continued operations. The loss or damage of any of our business relationships and or revenues derived therefore will result in the inability to market and produce our products.

### **Our success may be dependent on foreign markets**

Foreign and ancillary markets are expected to generate the majority of our revenues from the medical and recreational cannabis industries. Neither foreign nor ancillary markets provide a guarantee of revenue. Many markets may never legalize the consumption of recreational cannabis, which limits the demand for our CO2 extractors. Also, licensing in foreign markets may be dependent upon performance in home markets and if our extractors is not a success or if, for any reason, it is not well-received by the public, it may be a financial failure.

### **Foreign rules and regulations may have an adverse impact on our operations**

Some foreign countries may impose government regulations on the distribution of our products. Also revenues derived from the distribution of our products in foreign countries, if any, may be subject to currency controls and other restrictions that may temporarily or permanently prevent our ability to receive or account for such revenue. To the extent that we have made the economic decision to pursue a particular project based upon foreign distribution, our operations may suffer.

### **US Related Risk Factors**

Marijuana remains illegal under U.S. federal law and the approach to enforcement of U.S. federal laws against marijuana is subject to change. Management is not aware of any State or Federal laws or regulation specifically related to the use of the Corporation's CO2 extractors for the extraction of cannabinoids from marijuana. Furthermore, purchasers of the Corporation's extractors are required to confirm they are of legal age in their jurisdiction, will not use the purchased product(s) for illegal activities, and will comply with local laws and regulations. However, notwithstanding such approach, it could be that federal and/or State laws could be interpreted in a way that results in adverse enforcement action resulting in a direct negative effect on the Corporation's sales in the U.S. and such negative effect could cause the Corporation to fail and investors could lose all of their investment. The Corporation's marijuana-related activities (i.e., selling extractors that could be used to extract cannabinoids from marijuana) target the medical segment of the overall marijuana market. Unlike in Canada which has federal legislation uniformly governing the cultivation, distribution, sale, and possession of medical cannabis under the ACMPR, investors are cautioned that in the United States, cannabis is largely regulated at the state level. But it should be noted that in spite of the permissive regulatory environment of medical cannabis in many states within the United States, cannabis continues to be categorized as a controlled substance under the US federal Controlled Substances Act and as such, violates federal law in the United States. The United States Congress has passed appropriation bills each of the last three years that have not appropriated funds for prosecution of cannabis offenses of individuals who are in compliance with state medical cannabis laws. American courts have construed these

# MedXtractor Corp.

## Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

appropriations bills to prevent the federal government from prosecuting individuals when those parties comply with state law. However, because this conduct continues to violate federal law, American courts have observed that should Congress, at any time, choose to appropriate funds to fully prosecute the Controlled Substances Act, any individual or business, even those who have fully complied with state law, could be prosecuted for violations of federal law. Violations of federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities, or divestiture. The Corporation is not aware of any non-compliance with U.S. federal law; however, if the Corporation was found to be non-compliant, this could have a material adverse effect on the Corporation, including its reputation and ability to conduct business, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for the Corporation to estimate the time or resources that would be needed for the investigation of such matters or its final resolution. The Corporation plans to sell extractors into the US and these sales will be subject to US federal and state laws. Given the illegality of marijuana under U.S. federal law the issuer's access to capital could be negatively affected by public and/or private capital not being available to support continuing operations. At present, management believes that both private and public capital is available to the Corporation on terms acceptable to the Corporation but management also believes that this capital availability could change without notice, requiring the Corporation to operate solely on internally-generated funds. In the event that the Corporation has insufficient internally-generated funds the Corporation could fail and you could lose all of your investment. Management is not currently aware of any specific US federal or state initiatives that would lessen the Corporation's capital access. Management has reviewed US federal and state requirements related to the sale of its extractors and believes that there are no federal laws pertaining to the use of its extractors for extracting marijuana by licensed operators. States typically have regulations related to mechanical aspects of equipment such as the Corporation's extractors with compliance required by the operator of the subject equipment in that operator's jurisdiction. The Corporation sells its extractors F.O.B Alberta and management believes that because of this, the compliance requirement transfers, to the buyer, in Alberta. Management believes it is in compliance with Alberta regulation and is not aware of non-compliance with any US federal or state law or regulation.

### **The Corporation's Risks**

**We have a limited history of operations and unless we are able to successfully execute our business plan, our business and operating results may suffer resulting in the complete failure of our business**

Our operations are subject to all of the risks inherent in the establishment of a new business. The likelihood of our success must be considered in light of the risks, problems, expenses and delays frequently encountered in connection with the formation of a new business in general, as well as the highly competitive environment in which the business is operating. To address these risks, we must, among other things, continue to respond to competitive developments, product failure causing personal injury and property damage, attract, retain and motivate qualified personnel, commercialize products, and implement and successfully execute our marketing strategy and advertising sales strategy. There can be no assurance that we will be successful in addressing such risks.

**We will incur increased costs and demands upon management as a result of complying with the laws and regulations affecting public companies, which could harm our operating results**

As a public company, we incur significant additional legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements. We expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly.

**We are currently dependent on our officers and directors for our success and our future operations may require that we can attract and retain qualified employees, which we may not be able to do**

# MedXtractor Corp.

## Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

Our current operations are managed by our officers and directors, should our officers and directors resign, we would have no personnel to undertake the operations of the Corporation and therefore the Corporation would be adversely affected. We have no key-person insurance policy for our President or any other Officers and/or Directors and at this time we have no intention of acquiring same. Our future operations may depend, in part, on our ability to attract, employ and retain additional qualified employees. No assurance can be given that we will be able to attract or retain such personnel, if required.

### **We will rely on consultants and employees and if we are unable to retain these or other similarly qualified individuals, we may not be able to carry out our business operations**

We expect to be dependent upon contract service providers and loss of their services could adversely affect our business and our ability to maintain our operations or develop new products. We have not entered into any employment or non-competition agreements with any individuals and do not plan to in the future. Our success will depend on our ability to attract and retain qualified personnel. If we cannot attract and retain the necessary individuals our operating results will suffer.

Costs associated with our business, including production and input costs are not fixed and might increase, creating uncertainty about our ability to meet our plan of operations.

We have not established long-term contracts with our consultants or other third party suppliers we intend to rely on for the component parts of the CO2 extractors. The lack of long-term contracts could result in an increase in what we pay these individuals for their services. An increase in the production costs will reduce our margins and might make our projects uneconomical leading to the failure of our business.

### **While we have US and Canadian patents, litigation arising out of infringement or other commercial disputes could cause us to incur expenses and impair our competitive advantage**

We may incur substantial expenses in defending against prospective claims, regardless of their merit. Our success depends in part on our ability to enforce intellectual property protection for our concepts and to preserve our trade secrets. The validity and breadth of claims covered in our patent filed with Canadian and U.S. authorities involve complex legal and factual questions and, therefore, may be subject to challenge. No assurances can be given that any of our patents will be held valid if subsequently challenged, or that others will not claim rights in, or ownership of, the potential copyrights or trademarks or other proprietary rights held by us or that our intellectual property will not infringe, or be alleged to infringe, the proprietary rights of others. Furthermore, there can be no assurance that others have not developed or will not develop similar concepts to our CO2 extractor. In addition, whether or not additional intellectual property protection is issued to the Corporation, others may hold or receive intellectual protection covering concepts that were subsequently developed by the Corporation; and no assurance can be given that others will not or have not independently developed or otherwise acquired substantially equivalent intellectual property.

### **Our products operate under pressure and various jurisdictions have regulations around pressured products**

Almost all jurisdictions have rules and regulations related to pressurized vessels and without an exemption, our products may be unsaleable without certification. Certification is often a matter of passing operating specification tests and paying fees but there is no guarantee that any relevant authority will not change certification processes and that any such changes would not render our products unsaleable in the applicable jurisdiction. Such changes could cause a material decrease in our sales and profitability and could put the Corporation out of business in which case you could lose your entire investment.

# MedXtractor Corp.

## Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

### **Service and Warranty Risks**

The Corporation's products are technical in nature and are sold with a one year limited warranty and a product return policy. There is no certainty the products will operate as expected and this could result in the return of a significant number of extractors or result in expensive warranty claims. Any combination of the aforementioned may result in the failure of the Corporation and a loss of your investment.

### **Insufficient Capital**

The Corporation currently has revenue producing operations but may, from time to time, report a working capital deficit. To maintain its activities, the Corporation may require additional funds which may be obtained either by the sale of equity capital or by entering into an option or joint venture agreement with a third party providing such funding. There is no assurance that the Corporation will be successful in obtaining such additional financing; failure to do so could result in failure of the Corporation and total loss of your investment.

### **Financing Risks**

The Corporation has no history of significant earnings and, due to the nature of its business, there can be no assurance that the Corporation will be profitable. The Corporation has paid no dividends on its shares since incorporation and does not anticipate doing so in the foreseeable future.

### **Patent Risks**

Although the Corporation has exercised the usual due diligence with respect to determining title to patents and patent applications in which it has a material interest, there is no guarantee that title to such assets will not be challenged or impugned. The Corporation's patent application interests may be subject to prior unregistered agreements or transfers and title may be affected by undetected defects.

### **Foreign Currency Risk**

Foreign currency fluctuations may affect the cash flow which the Corporation may realize from its operations, since most of its product sales are expected to occur in US dollars whereas the Corporation's costs are incurred primarily in Canadian dollars.

### **Conflicts of Interest**

Certain of the directors and officers of the Corporation are engaged in, and will continue to engage in, other business activities on their own behalf and on behalf of other companies and, as a result of these and other activities, such directors and officers of the Corporation may become subject to conflicts of interest. The ABCA provides that in the event that a director has an interest in a contract or proposed contract or agreement, the director shall disclose his interest in such contract or agreement and shall refrain from voting on any matter in respect of such contract or agreement unless otherwise provided under the ABCA. To the extent that conflicts of interest arise, such conflicts will be resolved in accordance with the provisions of the ABCA. To the Corporation's knowledge, as at the date hereof there are no existing or potential material conflicts of interest between the Corporation and a director or officer of the Corporation.

### **Intellectual Property**

We have a US patent that was granted on May 14, 2019 - US 10,286,336 B2 and the Canadian patent received September 10, 2020.

### **Insurance**

Directors and Officers liability insurance policy commenced March 15, 2020.

# MedXtractor Corp. Management Discussion and Analysis

*For the three and nine months ended November 30, 2020*

## Additional Information

Additional information regarding the Company and its business and operations is available on the Company's profile at [www.sedar.com](http://www.sedar.com) and on the Company's website at [medxtractor.com](http://medxtractor.com).

## Corporate Information

### BOARD OF DIRECTORS:

James Durward  
G. Steven Price <sup>(1)</sup>  
Dusan Kuzma <sup>(1)</sup>  
Gordon Crawford

1) Member of Audit Committee

### OFFICERS:

James Durward	-	President, Chief Executive Officer, Corporate Secretary
Dwayne A. Vinck	-	Chief Financial Officer

### STOCK EXCHANGE LISTING:

CSE:MXT

### AUDITORS:

MNP LLP  
Calgary, Alberta

### LEGAL COUNSEL:

Heighington Law  
Calgary, Alberta

### REGISTRAR AND TRANSFER AGENT:

TSX Trust Company,  
Calgary, Alberta